Modified arginine deiminase

Details Modified arginine deiminase Modified arginine deiminase

1998-02-13

2001-02-06

Weber, Jon P. (Department: 1651)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Oxidoreductases

C435S180000, C435S188000, C435S191000, C435S181000

Reexamination Certificate

active

06183738

ABSTRACT:

FIELD OF THE INVENTION
The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods for treating cancer, and to methods for treating and/or inhibiting metastasis.
BACKGROUND OF THE INVENTION
Malignant melanoma (stage 3) and hepatoma are fatal diseases which kill most patients within one year of diagnosis. In the United States, approximately 16,000 people die from these diseases annually. The incidence of melanoma is rapidly increasing in the United States and is even higher in other countries, such as Australia. The incidence of hepatoma, in parts of the world where hepatitis is endemic, is even greater. For example, hepatoma is one of the leading forms of cancer in Japan and Taiwan. Effective treatments for these diseases are urgently needed.
Selective deprivation of essential amino acids has been used to treat some forms of cancer. The best known example is the use of L-asparaginase to lower levels of asparagine as a treatment for acute lymphoblastic leukemia. The L-asparaginase most frequently used is isolated from
E. coli.
However, clinical use of this enzyme is compromised by its inherent antigenicity and short circulating half-life, as described by Y. K. Park, et al,
Anticancer Res.,
1:373-376 (1981). Covalent modification of
E. coli
L-asparaginase with polyethylene glycol reduces its antigenicity and prolongs its circulating half-life, as described, for example, by Park,
Anticancer Res., supra;
Y. Kamisaki et al,
J. Pharmacol. Exp. Ther.,
216:410-414 (1981); and Y. Kamisaki et al,
Gann.,
73:47-474 (1982). Although there has been a great deal of effort to identify other essential amino acid degrading enzymes for the treatment of cancer, none have been approved, primarily because deprivation of essential amino acids, by definition, results in numerous, and severe, side effects.
It has been reported that enzymes which degrade non-essential amino acids, such as arginine, may be an effective means of controlling some forms of cancer. For example, arginine deiminase (ADI) isolated from
Pseudomonas pudita
was described by J. B. Jones, “The Effect of Arginine Deiminase on Murine Leukemic Lymphoblasts,” Ph.D. Dissertation, The University of Oklahoma, pages 1-165 (1981). Although effective in killing tumor cells in vitro, ADI isolated from
P. pudita
failed to exhibit efficacy in vivo because it had little enzyme activity at a neutral pH and was rapidly cleared from the circulation of experimental animals. Arginine deiminase derived from
Mycoplasma arginini
is described, for example, by Takaku et al,
Int. J. Cancer,
51:244-249 (1992), and U.S. Pat. No. 5,474,928, the disclosures of which are hereby incorporated by reference herein in their entirety. However, a problem associated with the therapeutic use of such a heterologous protein is its antigenicity. The chemical modification of arginine deiminase from
Mycoplasma arginini,
via a cyanuric chloride linking group, with polyethylene glycol was described by Takaku et al.,
Jpn. J. Cancer Res.,
84:1195-1200 (1993). However, the modified protein was toxic when metabolized due to the release of cyanide from the cyanuric chloride linking group.
There is a need for compositions which degrade non-essential amino acids and which do not have the problems associated with the prior art. The present invention is directed to these, as well as other, important ends.
SUMMARY OF THE INVENTION
The present invention is directed to arginine deiminase modified with polyethylene glycol. In a preferred embodiment, the arginine deiminase is modified with polyethylene glycol, having a total weight average molecular weight of about 1,000 to about 50,000, directly or through a biocompatible linking group.
Another embodiment of the invention is directed to methods of treating cancer, including, for example, sarcomas, hepatomas and melanomas. The invention is also directed to methods of treating and/or inhibiting the metastasis of tumor cells.
These and other aspects of the present invention will be elucidated in the following detailed description of the invention.


REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 5372942 (1994-12-01), McGarrity et al.
patent: 5447722 (1995-09-01), Lang et al.
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5474928 (1995-12-01), Takaku et al.
patent: 5804183 (1998-08-01), Filpula et al.
patent: 0 372 752 A2 (1990-06-01), None
patent: 53490 (1990-02-01), None
patent: 4-121187 (1992-04-01), None
patent: 94/05332 (1994-03-01), None
patent: 96/34015 (1996-10-01), None
Pierce, “Handbook & General Catalog”, pp. 283-311, 1989.
Abuchowski, A. et al., “Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase”,J. Biol. Chem., 1977, 252(11),3582-3586.
Abuchowski, A. et al., “Treatment of L5178Y Tumor-Bearing BDF Mice with a Nonimmunogneic L-Glutaminase-L-Asparaginase”,Cancer Treat. Rep., 1979, 63(6), 1127-1132.
Gill, P. et al., “Inhibition of cell division in L5178Y cells by arginine-degrading mycoplasmas: the role of arginine deiminase”,Can J. Microbiol., 1970, 16, 415-419.
Habeeb, A.F.S.A, “Determination of Free Amino Groups in Proteins by Trinitrobenzenesulfonic Acid ”,Analyt. Biochem., 1996, 14, 328-336.
Hershfield, M.S. et al., “Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol-Modified Adenosine Deaminase”,New Engl. J. Medicine, 1987, 316(10), 589-596.
Jaffe, N. et al., “Favorable Remission Induction Rate with Twice Weekly Doses of L-Asparaginase”,Cancer Res., 1973, 33(1), 1-4.
Jones, J.B., “The Effect of Arginine Deiminase on Murine Leukemic Lymphoblasts”, Ph.D Dissertation, The University of Oklahoma, 1981, 1-165.
Kamisaki et al., “Increased Antitumor Activity ofEscherichia ColiL-Asparaginase By Modification with Monomethoxypolyethylene Glycol”,Gann., 1982, 73, 470-474.
Kamisaki et al., “Reduction in Immunogenicity and Clearance Rate ofEscherichia coliL-Asparaginase by Modification with Monomethoxypolyethylene Glycol”,J. Pharmacol. Exp. Ther., 1981, 216(2), 410-414.
Kidd, J.G., “Asparaginase and Cancer—Yesterday and Today”,Cancer Res., 1970, 33, 1-14.
Kondo, K. et al., “Cloning and sequence analysis of the arginine deiminase gene fromMycoplasma arginini”, Mol. Gen. Genet., 1990, 221, 81-86.
Misawa, S. et al., “High-level expression of Mycoplasma arginine deiminase inEscherichia coliand its efficient renaturation as an anti-tumor enzyme”,J. Biotechnology, 1994, 36, 145-155.
Miyasaki, K. et al., “Potent Growth Inhibition of Human Tumor Cells in Culture by Arginine Deiminase Purified from a Culture of a Mycoplasma-infected Cell Line”,Cancer Res., 50, 4522-4527.
Monfardini, C. et al., “A Branched Monomethoxypoly(ethylene glycol) for Protein Modification”,Bioconj. Chem., 1995, 6, 62-69.
Naoi, M. et al., “Alteration of the Substrate Specificity ofAspergillus oryzae&bgr;-Galactsidase by Modification with Polyethylene Gycol”,J. Appl. Biochem., 1984, 6, 91-102.
Oginsky, “[92] Isolation and Determination of Arginine and Citrulline”,Meth. Enzymol., 1957, 3, 639-642.
Ohno, T. et al., “Cloning and Nucleotide Sequence of the Gene Encoding Arginine Deiminase ofMycoplasma arginini”, Infect. Immun., 1990, 58, 3788-3795.
Park, Y.K. et al., “Pharmacology ofEscherichia Coli-L-Asparaginase Polyethylene Gycol Adduct”,Anticancer Res., 1981, 1, 373-376.
Pyatak, P.S. et al., “Preparation of a Polyethylene Gycol: Superoxide Dismutase Adduct, and an Examination of its Blood Circulating Life and Anti-Inflammatory Activity”,Res. Commun. Chem. Path. Pharmacol., 1980, 29(1), 113-127.
Sayers, J.R. et al., “Rapid High-Efficiency Site-Directed Mutagenesis by the Phosphorothioate Approach”,Biotechniques, 1992, 13(4), 592-596.
Stocks, S.J. et al., “A Fluorometric Assay of the Degree of Modification of Protein Primary Amines with Polyethylene Gycol”,Analyt. Biochem., 1986, 154, 232-234.
Su, T. et al., “Cloning of cDNA for Argininosuccinate Synthetase mRNA and Study of Enzyme Overproduction in a Human Cell Line”,J. Biol. Chem., 1981, 256(22), 11826-11831.
S

Affiliated with

Also associated with

Rating

Modified arginine deiminase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified arginine deiminase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified arginine deiminase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2600396